2-MAPB Stats & Data

Reasoning for additions/changes (harm‑reduction justifications):

- Adulteration and mislabeling are common in unregulated markets; Erowid’s DrugsData program and European drug checking services consistently find unexpected contents. Therefore, always reagent‑test and, where possible, use a laboratory drug‑checking service before dosing.

- Overheating and over‑hydration are both established risks with serotonergic entactogens. Use cooling/rest breaks; sip fluids regularly but avoid excessive plain water. Prefer electrolyte‑containing drinks or salty snacks to prevent hyponatremia.

- Serotonergic polypharmacy meaningfully increases the chance of serotonin toxicity. Avoid combinations with MAOIs, SSRIs/SNRIs, tramadol, DXM, and similar agents. This is reflected in TripSit's interaction guidance and community safety lists.

- Reports with benzofurans (e.g., 5‑MAPB) frequently include jaw tension/bruxism, vasoconstriction, insomnia, and desire to redose; magnesium may reduce jaw clenching for some, but evidence is anecdotal—do not exceed daily limits. Keep doses modest and avoid stacking stimulants.

- Space sessions widely (commonly ≥4–6 weeks) to reduce mood dips and tolerance; frequent MDMA‑like use worsens after‑effects. This timing is an inference from MDMA harm‑reduction practice and reported hangovers.

- Insufflation is more likely to cause local irritation and sharp cardiovascular peaks; oral is generally safer/steadier for benzofurans per community experience.

- During long, hot, or high‑exertion settings (clubs/festivals), plan for cooling, electrolytes, and set dose limits in advance to avoid compulsive redosing.